Page 352 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

326 Vanessa Quick and John Kirwan

[6] Prieto-González S, Arguis P, García-Martínez A, et al. Large vessel involvement in
biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients
using CT angiography. Ann. Rheum. Dis., 2012; 71:1170–1176.

[7] Salvarani C, Pipitone N, Versari A, et al. Clinical features of polymyalgia rheumatica
and giant cell arteritis. Nat. Rev. Rheumatol., 2012; 8:509-521.

[8] Younge BR, Cook BE, Bartley GB, et al. Initiation of glucocorticoid therapy: before or
after temporal artery biopsy? Mayo Clin. Proc., 2004; 79:483-91.

[9] Hayreh SS, Podhajsky PA, Raman R, et al. Giant cell arteritis: Validity and reliability
of various diagnostic criteria. Am. J. Ophthalmol., 1997; 123: 285-296.

[10] Phillip, R. Mortality in systemic vasculitis: a systematic review. Clinical and
Experimental Rheumatology 2008; 26(Suppl):S94 -S104.

[11] Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the
management of large vessel vasculitis. Ann. Rheum. Dis., 2009; 68:318-323.

[12] Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management
of giant cell arteritis. Rheumatology, 2010; 49:1594-1597.

[13] Quick V, Kirwan JK. Our approach to the diagnosis and treatment of polymyalgia
rheumatica and giant cell (temporal) arteritis. J. R. Coll Physicians Edinb. 2012;
42:341-9.

[14] Patil P, Karia N, Jain S et al. Giant cell arteritis: a review. Eye and Brain 2013:5 23–33.
[15] Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset

rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis
Rheum. 2011; 63:633-639.
[16] Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of
Giant Cell Arteritis and Polymyalgia Rheumatica. Arthritis Care & Research, 2009;
61:1454-1461.
[17] Smith CA, Fidler WJ, Pinals RS. The epidemiology of giant cell arteritis: report of a
ten-year study in Shelby County, Tennessee. Arthritis Rheum. 1983; 26:1214-1219.
[18] Wigley RD, Zhang NZ, Zeng QY, et al. Rheumatic diseases in China: ILAR-China
study comparing the prevalence of rheumatic symptoms in northern and southern rural
populations. J. Rheumatol., 1994; 21:1484e90.
[19] Kobayashi S, Yano T, Matsumoto Y, et al. Clinical and epidemiologic analysis of giant
cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first
government-supported nationwide survey. Arthritis Rheum. 2003; 49:594–598.
[20] Pereira LS, Yoon MK, Hwang TN, et al. Giant cell arteritis in Asians: a comparative
study. Br. J. Ophthalmol., 2011; 95:214–216.
[21] Liozon E, Ouattara B, Rhaiem K et al. Familial aggregation in giant cell arteritis
polymyalgia rheumatica: a comprehensive literature review including 4 new families.
Clinical and Experimental Rheumatology, 2009; 27:S89-S94.
[22] Weyand CM, Hicok KC, Hunder GG, et al. The HLA-DRB1 locus as a genetic
component in giant cell arteritis: mapping of a disease-linked sequence motif to the
antigen binding site of the HLA-DR molecule. J. Clin Invest., 1992, 90:2355-2361.
[23] Borchers AT, Gershwin ME. Giant cell arteritis: A review of classification,
pathophysiology, geo-epidemiology and treatment. Autoimmunity Reviews, 2012;
11:A544-A554.
[24] Ly K, Regent A, Tamby M, et al. Pathogenesis of giant cell arteritis: More than just an
inflammatory condition? Autoimmunity Reviews 2010; 9:635-645.

Complimentary Contributor Copy